"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-01

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

correlate the serum level of statin and SGLT2i when given as polytherapy with HPLC in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients

NCT05895123

ST-segment Elevation Myocardial Infarction

COMPLETED PHASE2

Pleiotropism of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe

NCT01241097

Endothelial Function

UNKNOWN NA

Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity

NCT05792293

Doxorubicin Induced Cardiomyopathy

UNKNOWN PHASE2/PHASE3

Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin

NCT05500937

Diabetes Mellitus

UNKNOWN PHASE2/PHASE3

Plant Sterols Effect on Previous Statin Therapy

NCT02089867

Coronary Artery Disease

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective study that will carried out in Department of cardiology, Faculty of Medicine, Fayoum University during the period from 1 April 2024 to 1 Juley 2024. The study includes 90 Outpatients Clinic patients who met the inclusion criteria. Patients will provide written informed consent before involving in this study.

* we will split the 90 patients into three groups:

1. 30 patients will take statin.
2. 30 patients will take SGLT2i.
3. 30 patients will take both of statin and SGLT2i.
* By collecting their blood samples and calculate the serum level of statin by using HPLC and calculate plasma level of SGLT2i by using HPLC as baseline first then after three months to predict the effect of each drug to another one, we will follow their cholesterol, triglyceride, low density lipo-protein and high density lipo-protein and we will also inspect their adverse effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

2 Drugs Are Statin and SGLT2i

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

* we include patients established ischemic heart failure seen by a primary care provider to diagnose ischemic heart disease,
* They assessed the use of statin with SGLT2i.

Exclusion Criteria

* We exclude patients with

1. liver dysfunction.
2. renal dysfunction.
3. fungal infection.
4. coagulation disorder.
5. Pts using drugs that interact with SGLT2i.
6. patients that will refuse to be enrolled in the Study or refuse to write informed consent.

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No